Viking Therapeutics fell 3crashdrive3nintendoswitch.22%crashdrive3nintendoswitch, Lilly fell 1.4%, Amgen fell 1.34%, and Novo Nordisk fell 1.25%. In the news, Swiss competitor Roche announced that its Phase 1 trial of GLP-1/GIP dual receptor agonist CT-388 achieved positive results in obese people. Compared with placebo, CT-388 administered subcutaneously once a week for 24 weeks in healthy obese adults significantly lost weight, with a placebo-adjusted average weight loss rate of 18.8% (p-value
